Targeting Therapy-Resistant Cancer with Radiotheranostics: Preclinical Insights from ALDH1A1- Directed Development
11:00 am - Thursday 3rd December 2026
- Presenting preclinical data supporting the development of ALDH1A1-targeted radiotheranostics in therapy-resistant cancers
- Exploring the rationale for targeting resistance-associated biology and assessing its potential to address unmet clinical need
- Evaluating the translational challenges associated with advancing novel intracellular targets toward clinical development